ESC 365 - Discussant review - Quantitative Understanding of Obstruction Impact of Aficamten in HCM

Back

HFA Premium Access

Discussant review - Quantitative Understanding of Obstruction Impact of Aficamten in HCM

Session: Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy

Topic: Hypertrophic Cardiomyopathy

Speaker: Professor P. Elliott (London, GB)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Professor Perry Mark Elliott

University College London, London (United Kingdom of Great Britain & Northern Ireland)

67 presentations

28 followers

9 more presentations in this session

Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial

Speaker: Professor F. Gustafsson (Copenhagen, DK)

Access

Slides

Video

Discussant review - ARIES

Speaker: Doctor O. Dar (London, GB)

Access

Slides

Video

Semaglutide therapy and diuretic use in obesity-related HFpEF: insights from the STEP-HFpEF programme

Speaker: Professor S. Verma (Toronto, CA)

Access

Slides

Video

Discussant review - STEP-HFpEF Programme

Speaker: Associate Professor D. Farmakis (Athens, GR)

Access

Slides

Video

Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial

Speaker: Doctor M. Maron (Burlington, US)

Access

Slides

Video

Access the full session

Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy

Speakers: Professor P. Elliott, Professor F. Gustafsson, Doctor O. Dar, Professor S. Verma, Associate Professor D. Farmakis...

Access

Video

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources